Investment Advisor, PN Vijay is of the view that is of the view that one should just hold Ranbaxy Laboratories.

Vijay told CNBC-TV18, "Ranbaxy has been hitting the news forever for the wrong reasons, locking horns with the GSKs and Pfizer of the world. At least their lawyers must be less busy now. And the big payment also, which is coming in, exclusivity. So this portion of it is very good. Whether it is enough to take the share out of the total rut it has fallen into, we need a bit more of this type of stuff because time and again, we have seen Ranbaxy get some nice news, go up to Rs 400 and then fall back to Rs 350. We are not sure whether the negative feeling about the whole industry will still affect it. Right now one can just hold it."